Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.The Gruenenthal Group and Forest Laboratories said that Gruenenthal and Forest Laboratories Ireland, a wholly owned subsidiary of Forest Laboratories, have entered into a license agreement for the co-development and commercialisation of a novel oral small molecule analgesic, GRT 6005, and its follow-on compound GRT 6006.
Subscribe to our email newsletter
Both compounds were discovered and developed by Gruenenthal and represent novel molecules with pharmacological and pharmacokinetic profiles that may enhance their effect in certain pain conditions.
GRT 6005 has successfully completed initial proof-of-concept studies in nociceptive and neuropathic pain with further Phase 2 studies planned prior to initiation of Phase 3.
The license agreement provides that Forest pay Gruenenthal an undisclosed upfront license payment in addition to development and commercialisation milestones and royalties on net sales.
Under the agreement, Forest will have exclusive rights in the US and Canada with an option to co-promote in Europe.
However, Gruenenthal will have an option to co-promote in the US and Canada and the development costs will be shared between the parties according to an undisclosed formula.
Forest chairman and CEO Howard Solomon said that the unique of the licensed molecules may provide needed alternative analgesic options for patients.
"We look forward to working with Gruenenthal to make this novel class of products available to the millions of patients suffering from moderate to severe pain, Solomon said.